

Ayman Samman Tahhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11832766/publications.pdf>

Version: 2024-02-01

38
papers

1,359
citations

331670

21
h-index

345221

36
g-index

38
all docs

38
docs citations

38
times ranked

2309
citing authors

#	ARTICLE	IF	CITATIONS
1	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. ESC Heart Failure, 2021, 8, 26-36.	3.1	6
2	Marital status and outcomes in patients with cardiovascular disease. Trends in Cardiovascular Medicine, 2020, 30, 215-220.	4.9	64
3	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circulation: Heart Failure, 2020, 13, e006605.	3.9	55
4	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. JAMA Cardiology, 2020, 5, 714.	6.1	76
5	Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine, 2020, 382, 416-426.	27.0	149
6	Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1032-1042.	7.1	68
7	Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease. Journal of the American Heart Association, 2020, 9, e015515.	3.7	15
8	Trends in prevalence of comorbidities in heart failure clinical trials. , 2020, 22, 1032.		1
9	Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1884-1892.	2.4	7
10	Representativeness of a Heart Failure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	4.1	30
11	Living in Food Deserts and Adverse Cardiovascular Outcomes in Patients With Cardiovascular Disease. Journal of the American Heart Association, 2019, 8, e010694.	3.7	57
12	Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?. JACC: Heart Failure, 2019, 7, 267-271.	4.1	13
13	Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation. International Journal of Cardiology, 2019, 276, 255-260.	1.7	5
14	Sleep Duration and Mortality in Patients With Coronary Artery Disease. American Journal of Cardiology, 2019, 123, 874-881.	1.6	16
15	High-Sensitivity Troponin and Coronary Artery Disease Severity. JACC: Cardiovascular Imaging, 2019, 12, 1056-1057.	5.3	1
16	High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Long-Term Outcomes. Journal of the American Heart Association, 2018, 7, .	3.7	57
17	Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes. Circulation Research, 2018, 122, 1565-1575.	4.5	35
18	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. Current Heart Failure Reports, 2018, 15, 10-16.	3.3	6

#	ARTICLE	IF	CITATIONS
19	Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. <i>European Journal of Heart Failure</i> , 2018, 20, 1068-1071.	7.1	17
20	Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2018, 121, 1461-1466.	1.6	11
21	Inflammatory response to mental stress and mental stress induced myocardial ischemia. <i>Brain, Behavior, and Immunity</i> , 2018, 68, 90-97.	4.1	41
22	Use of High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia. <i>Annals of Internal Medicine</i> , 2018, 169, 751.	3.9	16
23	Coronary and Peripheral Vasomotor Responses to Mental Stress. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	33
24	Circulating Progenitor Cells and Racial Differences. <i>Circulation Research</i> , 2018, 123, 467-476.	4.5	18
25	Differential Associations of Diastolic and Systolic Pressures With Cerebral Measures in Older Individuals With Mild Cognitive Impairment. <i>American Journal of Hypertension</i> , 2018, 31, 1268-1277.	2.0	21
26	Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 714-717.	4.1	8
27	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. <i>JAMA Cardiology</i> , 2018, 3, 1011.	6.1	146
28	Myocardial Ischemia and Mobilization of Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2018, 7, e007504.	3.7	7
29	Hemodynamic, catecholamine, vasomotor and vascular responses: Determinants of myocardial ischemia during mental stress. <i>International Journal of Cardiology</i> , 2017, 243, 47-53.	1.7	64
30	Sex Differences in Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	31
31	Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. <i>Atherosclerosis</i> , 2017, 264, 108-114.	0.8	27
32	Association between oxidative stress and atrial fibrillation. <i>Heart Rhythm</i> , 2017, 14, 1849-1855.	0.7	90
33	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	40
34	Interleukin Antagonists. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	0
35	Marital Status and Outcomes in Patients With Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	54
36	Cohort profile: the Emory Cardiovascular Biobank (EmCAB). <i>BMJ Open</i> , 2017, 7, e018753.	1.9	26

#	ARTICLE	IF	CITATIONS
37	Trends in Heart Failure Clinical Trials From 2001â€“2012. Journal of Cardiac Failure, 2016, 22, 171-179.	1.7	22
38	Trends in characteristics of cardiovascular clinical trials 2001-2012. American Heart Journal, 2015, 170, 263-272.e2.	2.7	26